BCL2 Overexpression

CI-VAR-00003126Explore in graph →CIViC 152

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Diffuse Large B-Cell Lymphoma2
BCL2 Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID423 In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival. PMID 9207459 · Gascoyne et al., 1997 · Open in CIViC	civic
BCL2 Overexpression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	rejected	EID424 In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS. PMID 9207459 · Gascoyne et al., 1997 · Open in CIViC	civic
Lymphoma1

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.